Compare ADMA Biologics Inc (ADMA) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Vanguard Mega Cap Growth ETF — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Vanguard Mega Cap Growth ETF trades at $87.22. The key difference: Vanguard Mega Cap Growth ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | MGK | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $20.38 | $92.06 |
52-Week Low | $7.60 | $70.70 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
MGK trades at $88.29, up 1.47% today, with a bullish technical signal from moving averages but bearish oscillators. The ETF completed a 1:5 stock split in April 2026 and announced a $0.08 dividend for H1-2026. News highlights potential inclusion of SpaceX and emphasizes MGK's low 0.05% expense ratio and heavy concentration in mega-cap tech stocks, which have driven historical outperformance versus the S&P 500.
Outlook remains positive due to exposure to high-growth tech giants, though concentration risk and overbought technicals near-term pose challenges. Long-term growth potential is supported by earnings momentum, but investors face volatility from sector rotations and valuation sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
